Cu-II(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord
AuthorHilton, JB; Mercer, SW; Lim, NKH; Faux, NG; Buncic, G; Beckman, JS; Roberts, BR; Donnelly, PS; White, AR; Crouch, PJ
Source TitleSCIENTIFIC REPORTS
PublisherNATURE PUBLISHING GROUP
University of Melbourne Author/sHilton, James; Roberts, Blaine; Donnelly, Paul; White, Anthony; Crouch, Peter; Faux, Noel; Mercer, Stephen; LIM, NASTASIA; BUNCIC, GOJKO
AffiliationFlorey Department of Neuroscience and Mental Health
Microbiology and Immunology
Pharmacology and Therapeutics
School of Chemistry
Document TypeJournal Article
CitationsHilton, J. B., Mercer, S. W., Lim, N. K. H., Faux, N. G., Buncic, G., Beckman, J. S., Roberts, B. R., Donnelly, P. S., White, A. R. & Crouch, P. J. (2017). Cu-II(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord. SCIENTIFIC REPORTS, 7 (1), https://doi.org/10.1038/srep42292.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304223
Ubiquitous expression of mutant Cu/Zn-superoxide dismutase (SOD1) selectively affects motor neurons in the central nervous system (CNS), causing the adult-onset degenerative disease amyotrophic lateral sclerosis (ALS). The CNS-specific impact of ubiquitous mutant SOD1 expression is recapitulated in transgenic mouse models of the disease. Here we present outcomes for the metallo-complex CuII(atsm) tested for therapeutic efficacy in mice expressing SOD1G93A on a mixed genetic background. Oral administration of CuII(atsm) delayed the onset of neurological symptoms, improved locomotive capacity and extended overall survival. Although the ALS-like phenotype of SOD1G93A mice is instigated by expression of the mutant SOD1, we show the improved phenotype of the CuII(atsm)-treated animals involves an increase in mature mutant SOD1 protein in the disease-affected spinal cord, where concomitant increases in copper and SOD1 activity are also evident. In contrast to these effects in the spinal cord, treating with CuII(atsm) had no effect in liver on either mutant SOD1 protein levels or its activity, indicating a CNS-selective SOD1 response to the drug. These data provide support for CuII(atsm) as a treatment option for ALS as well as insight to the CNS-selective effects of mutant SOD1.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
- Minerva Elements Records 
- Chancellery Research - Research Publications 
- School of Chemistry - Research Publications 
- Pharmacology and Therapeutics - Research Publications 
- Pathology - Research Publications 
- Microbiology & Immunology - Research Publications 
- Clinical Pathology - Research Publications 
- Florey Department of Neuroscience and Mental Health - Research Publications